gemcitabine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 34 (66.67) | 24.3611 |
| 2020's | 17 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Adelantado, EZ; Beck, JT; Campone, M; Chan, A; Couillebault, XM; De Laurentiis, M; Duhoux, FP; Fan, L; Greil, R; Guerreiro, N; Im, SA; Kim, SB; Kuemmel, S; Kuter, I; Kwong, A; Loirat, D; Lopez, RL; Lu, YS; Mataraza, J; Özgüroğlu, M; Sand-Dejmek, J; Scholz, CW; Singer, CF; Steger, GG; Tibau, A; Vega, E; Wimberger, P; Zamagni, C | 1 |
| Cai, L; Guo, X; Hu, X; Jiang, Z; Luo, J; Pan, Y; Shao, Z; Sun, T; Teng, YE; Wang, B; Wang, S; Wang, X; Wang, Z; Wu, J; Yan, M; Zhang, J; Zhao, Y | 1 |
| Aftimos, P; Andrić, Z; Beelen, A; Goel, S; Malik, R; O'Shaughnessy, J; Rugo, HS; Tan, AR; Yi, JS; Zhang, J | 1 |
| Han, J; Ma, Z; Wan, M; Yi, H | 1 |
| Bianchi, GV; Cantarelli, B; Capri, G; de Braud, F; Depretto, C; Fucà, G; Leporati, R; Ligorio, F; Lobefaro, R; Manoukian, S; Mariani, L; Peverelli, G; Presti, D; Pruneri, G; Rametta, A; Scaperrotta, G; Vernieri, C; Vingiani, A; Zattarin, E | 1 |
| Feng, X; Jiang, X; Lee, MJ; Li, Y; Lin, W; Liu, J; Mao, J; Weichselbaum, RR | 1 |
| Odoi, A; Pattarawat, P; Pfisterer, B; Wallace, S; Wang, HR | 1 |
| Cai, Y; Yao, D; Zheng, Q; Zhou, T | 1 |
| Cai, R; Chen, S; Chen, X; Chen, Y; Fan, Y; Guan, Y; Lan, B; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Zhang, P; Zhao, W | 1 |
| Li, H; Meng, R; Rui, M; Shang, Y; Shi, F | 1 |
| Daniele, MA; Menegatti, S; Schneible, JD; Young, AT | 1 |
| Bullock, TNJ; Price, RJ; Sheybani, ND; Thim, EA; Witter, AR; Yagita, H | 1 |
| Bartholomeusz, C; Devi, GR; Lee, J; Liu, H; Lu, AY; Pearson, T; Tripathy, D; Ueno, NT; Xie, X | 1 |
| Slater, H | 1 |
| Archibald, CJ; Hunt, JT; Pattarawat, P; Poloway, J; Wang, HR | 1 |
| Cao, J; Du, Y; Hu, X; Li, T; Liu, X; Tao, Z; Wang, B; Wang, L; Zhang, J; Zhu, Y | 1 |
| Ata, FK; Yalcin, S | 1 |
| Barajas, A; Evans, MA; Helgeson, ME; Krishnan, V; Menegatti, S; Mitragotri, S; Nowak, M; Pusuluri, A; Squires, TM; Vogus, DR; Zhang, M | 1 |
| Ding, T; Fan, Y; Gu, Z; Lin, G; Shi, Y; Wang, Q | 1 |
| Kai, M; Kubo, M; Nakamura, M; Yamada, M; Yamamoto, H | 1 |
| Wang, J; Wang, M; Wang, Z; Yang, Y; Zheng, R; Zou, W | 1 |
| DeVaux, RS; Espinal, R; Hepel, M; Herschkowitz, JI; Kurzatkowska, K; Santiago, T | 1 |
| Aktas, B; Bangemann, N; Braun, M; Christgen, M; Clemens, M; Forstbauer, H; Gluz, O; Grischke, EM; Hackmann, J; Harbeck, N; Kates, R; Kohls, A; Kreipe, HH; Kuemmel, S; Liedtke, C; Lindner, C; Nitz, U; Potenberg, J; Schumacher, C; Schumacher, J; Staib, P; Uleer, C; von Schumann, R; Warm, M; Wuerstlein, R | 1 |
| Ali, H; Barton, D; Bengala, C; Brufsky, A; Coleman, R; Conte, P; Cortes, J; de la Cruz-Merino, L; Eakel, J; Glück, S; Harbeck, N; Li, H; Miller, J; O'Shaughnessy, J; Schneeweiss, A; Shtivelband, M; Wilks, S; Yardley, DA; Young, R | 1 |
| Bianchi, G; Capri, G; Cona, MS; de Braud, F; Ferrari, B; Huber, V; Maggi, C; Manoukian, S; Mariani, G; Mennitto, A; Milano, M; Prisciandaro, M; Rinaldi, L; Rivoltini, L; Vernieri, C | 1 |
| Cao, J; Hu, XC; Lin, Y; Luo, JF; Shao, ZM; Sun, XJ; Tao, ZH; Wang, BY; Wang, LP; Wang, ZH; Wu, J; Yang, WT; Zhang, J; Zhang, S | 1 |
| André, F; Cortés, J; Dent, R; Deurloo, R; Easton, V; Gonçalves, A; Kümmel, S; Martín, M; Pollex, E; Schmid, P; Schuetz, F; Swain, SM | 1 |
| Alba, E; Awada, A; Bonnefoi, H; Charpentier, E; Coudert, B; Diéras, V; Emmons, GT; Garcia-Ribas, I; Gligorov, J; Jager, A; Lindeman, GJ; Paridaens, R; Pivot, X; Verweij, J; Zambelli, S | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Inagaki, A; Iwao, H; Izumi, Y; Miura, K; Nagayama, K; Shiota, M; Takahashi, K; Tanaka, M; Wanibuchi, H | 1 |
| Sinha, G | 1 |
| Ah Lee, S; Gwe Ahn, S; Jeong, J; Min Lee, H; Woo Lee, H | 1 |
| Di, G; Hu, X; Hu, Z; Liu, G; Liu, Y; Shao, Z; Wang, B; Wang, L; Wang, Z; Wu, J; Yang, W; Zhang, J | 1 |
| Inoue, K; Sonoda, T; Tsubamoto, H | 1 |
| Bryant, C; Massey, AJ; Rawlinson, R | 1 |
| Oguchi, K; Oyamada, H; Sasaki, A; Tsuchiya, H; Tsuji, M; Tsunoda, Y; Udaka, Y | 1 |
| Ehdaivand, S; Hardy, CW; Liang, D; Liu, EA; Madden, MZ; Pan, Y; Petrova, AV; Robinson, MH; Rudra, S; Smith, SC; Torres, MA; Wang, H; Wang, J; Wang, Y; Warren, MD; Yu, DS | 1 |
| Chen, XS; Garfield, DH; Huang, O; Shen, KW; Wu, JY; Yuan, Y | 1 |
| Carlson, RW; Charpentier, E; Danso, MA; Finn, RS; Garcia-Ribas, I; Hellerstedt, B; Miller, KD; Neubauer, M; O'Shaughnessy, J; Richards, P; Robert, N; Rugo, HS; Saleh, M; Schwartzberg, L; Specht, JM; Winer, EP; Yardley, DA | 1 |
| Cox, D; Dranitsaris, G; Faria, C; Gluck, S; Rugo, H | 1 |
| Chaturvedi, P; Gilkes, DM; Samanta, D; Semenza, GL; Xiang, L | 1 |
| Cai, L; Feng, JF; Gu, YJ; Hu, XC; Jiang, ZF; Liu, DG; Lou, GY; Luo, JF; Pan, YY; Ragaz, J; Shao, ZM; Sun, K; Teng, YE; Tong, ZS; Wang, BY; Wang, XJ; Wang, ZH; Wu, CP; Wu, J; Xu, BH; Yin, YM; Zhang, J | 1 |
| Abkevich, V; Carlson, RW; Chang, PJ; Dakhil, SR; Flaherty, PJ; Ford, JM; Goldstein, LJ; Haley, B; Hartman, AR; Head, B; Jensen, KC; Kurian, AW; Lipson, JA; Manola, J; Reid, JE; Schackmann, EA; Sparano, JA; Telli, ML; Timms, K; Vinayak, S; Wapnir, IL | 1 |
| Andergassen, U; Beckmann, MW; Bekes, I; DeGregorio, N; Deniz, M; Fasching, PA; Friedl, TW; Jaeger, B; Janni, W; Jueckstock, J; Kost, B; Lato, K; Neugebauer, J; Rack, B; Schneeweiss, A; Scholz, C; Schrader, I; Schramm, A; Schwentner, L; Trapp, E; Weissenbacher, T; Widschwendter, P | 1 |
| Barton, D; Beck, RM; Brufsky, A; Coleman, RE; Conte, PF; Cortes, J; Glück, S; Harbeck, N; Ko, A; Nabholtz, JM; O'Shaughnessy, J; Renschler, MF; Yardley, DA | 1 |
| Green, JE; He, S; Min, DJ | 1 |
| Daniel, BR; Eakle, JF; Hainsworth, JD; Lamar, RE; Lane, CM; Ward, PJ; Yardley, DA | 1 |
| Arpino, G; De Placido, S; Giuliano, M; Schettini, F | 1 |
| Hu, XC; Lin, C; Liu, MM; Tao, ZH; Wu, ZH; Zhang, J | 1 |
| Guan, X; Song, W; Tang, L; Wang, S; Xie, H; Xu, J; Xu, Y; Zhang, W | 1 |
| Aprelikova, O; Bennett, CN; Caplen, NJ; Chu, IM; Green, JE; Hollingshead, MG; Luger, D; Michalowski, AM; Mittereder, LR; Piwinica-Worms, H; Shou, J; Tomlinson, CC | 1 |
3 review(s) available for gemcitabine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Gemcitabine; Humans; Pyrimidines; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2022 |
Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carboplatin; Carcinoma, Ductal, Breast; Deoxycytidine; Epothilones; Female; Gemcitabine; Humans; Mastectomy; Multicenter Studies as Topic; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2016 |
18 trial(s) available for gemcitabine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Macrophage Colony-Stimulating Factor; Treatment Outcome; Triple Negative Breast Neoplasms | 2022 |
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Gemcitabine; Humans; Pyrimidines; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2022 |
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2020 |
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Paclitaxel; Progression-Free Survival; Triple Negative Breast Neoplasms | 2018 |
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Middle Aged; Neoplasm Metastasis; Neutrophils; Paclitaxel; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2018 |
Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Models, Biological; Paclitaxel; Patient Selection; Progression-Free Survival; Prospective Studies; Risk Assessment; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Mastectomy; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Placebos; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retreatment; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms; United States | 2014 |
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; BRCA1 Protein; BRCA2 Protein; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Profiling; Genomic Instability; Humans; Mastectomy, Segmental; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Body Mass Index; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Obesity; Overweight; Prognosis; Receptor, ErbB-2; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms; Young Adult | 2015 |
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Research Design; Survival Analysis; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Panitumumab; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Signal Transduction; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2016 |
31 other study(ies) available for gemcitabine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Regulation of DNA-PK activity promotes the progression of TNBC via enhancing the immunosuppressive function of myeloid-derived suppressor cells.
Topics: Animals; DNA; Gemcitabine; Leukocytes, Mononuclear; Mice; Myeloid-Derived Suppressor Cells; Triple Negative Breast Neoplasms | 2023 |
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
A Three-in-One Nanoscale Coordination Polymer for Potent Chemo-Immunotherapy.
Topics: Animals; Gemcitabine; Humans; Immunotherapy; Mice; Oxaliplatin; Polymers; Triple Negative Breast Neoplasms | 2023 |
Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cisplatin; Deoxycytidine; Depsipeptides; Drug Compounding; Female; Gemcitabine; Humans; Mice; Mice, Nude; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway.
Topics: Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inflammasomes; Interleukin-1beta; Nigericin; NLR Family, Pyrin Domain-Containing 3 Protein; Thiazolidines; Thiones; Triple Negative Breast Neoplasms; Up-Regulation; Wnt Signaling Pathway | 2020 |
Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Middle Aged; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Chitosan Hydrogels for Synergistic Delivery of Chemotherapeutics to Triple Negative Breast Cancer Cells and Spheroids.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Chitosan; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Compounding; Drug Liberation; Drug Synergism; Female; Gemcitabine; Humans; Hydrogels; Kinetics; Spheroids, Cellular; Triple Negative Breast Neoplasms | 2020 |
Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity.
Topics: Adaptive Immunity; Deoxycytidine; Female; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Immunosuppressive Agents; Triple Negative Breast Neoplasms | 2020 |
Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Dipeptides; Enzyme Inhibitors; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Nude; Triple Negative Breast Neoplasms | 2021 |
FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Double-Blind Method; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms; United States; United States Food and Drug Administration | 2020 |
A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Depsipeptides; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Reactive Oxygen Species; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer.
Topics: Annexin A6; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Exosomes; Gemcitabine; Humans; Lapatinib; Proteolysis; Triple Negative Breast Neoplasms; Ubiquitination | 2021 |
The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoplasm Proteins; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2022 |
A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Drug Liberation; Drug Synergism; Gemcitabine; Humans; Hyaluronic Acid; Mice; Mice, Inbred BALB C; Prodrugs; Triple Negative Breast Neoplasms | 2017 |
Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Liposomes; Nanostructures; Prodrugs; Taxoids; Triple Negative Breast Neoplasms | 2017 |
[Efficacy of GC Therapy for the Patient of iTNBC with Resistance to TAC Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Taxoids; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms | 2017 |
Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Demography; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2017 |
Surface-enhanced Raman scattering investigation of targeted delivery and controlled release of gemcitabine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Female; Folic Acid; Gemcitabine; Gold; Humans; Hydrogen-Ion Concentration; Metal Nanoparticles; Molecular Targeted Therapy; Spectrum Analysis, Raman; Transferrin; Triple Negative Breast Neoplasms | 2017 |
Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Proteome; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2013 |
Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bias; Carboplatin; Clinical Trials as Topic; Deoxycytidine; Drugs, Investigational; Female; Gemcitabine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Research Design; Treatment Failure; Triple Negative Breast Neoplasms | 2014 |
In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Ki-67 Antigen; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2014 |
Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Inflammatory Breast Neoplasms; Itraconazole; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Triple Negative Breast Neoplasms | 2014 |
Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Topics: Benzodiazepinones; Biomarkers, Tumor; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Indoles; MCF-7 Cells; Ovarian Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridones; Thiophenes; Triple Negative Breast Neoplasms; Urea | 2014 |
Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor.
Topics: Antineoplastic Agents; Apoptosis; BRCA1 Protein; Cell Line, Tumor; Cell Survival; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms | 2014 |
A gemcitabine sensitivity screen identifies a role for NEK9 in the replication stress response.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA Replication; Female; Gemcitabine; Humans; NIMA-Related Kinases; Protein Kinases; Protein Serine-Threonine Kinases; Replication Protein A; Stress, Physiological; Triple Negative Breast Neoplasms | 2014 |
Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Cytotoxins; Deoxycytidine; Disease-Free Survival; Female; Furans; Gemcitabine; Humans; Ketones; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2015 |
Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.
Topics: Analysis of Variance; Cell Line, Tumor; Deoxycytidine; DNA Primers; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1; Image Processing, Computer-Assisted; Immunoblotting; Interleukin-6; Interleukin-8; Kaplan-Meier Estimate; Luciferases; Microscopy; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Triple Negative Breast Neoplasms | 2014 |
Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Dipeptides; DNA Repair; Female; Gemcitabine; Humans; Indoles; Phosphorylation; Thiophenes; Triple Negative Breast Neoplasms; Urea | 2016 |
Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzodioxoles; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Focal Adhesion Kinase 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; Matrix Metalloproteinase 3; Octamer Transcription Factor-3; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; RNA, Small Interfering; src-Family Kinases; Survivin; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2016 |
PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
Topics: Base Sequence; BRCA1 Protein; Carboplatin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclins; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MicroRNAs; Middle Aged; Mutation; Neoplasm Invasiveness; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms; Up-Regulation | 2017 |
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cluster Analysis; Deoxycytidine; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mice; Protein Kinase Inhibitors; Protein Kinases; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA Interference; RNA, Small Interfering; Staurosporine; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2012 |